Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme

Emmanuel C. Nwokedi, Steven J. DiBiase, Salma Jabbour, Joseph Herman, Pradip Amin, Lawrence S. Chin

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Stereotactic radiosurgery (SRS) has become an effective therapeutic modality for the treatment of patients with glioblastoma multiforme (GBM). This retrospective review evaluates the impact of SRS delivered on a gamma knife (GK) unit as an adjuvant therapy in the management of patients with GBM. METHODS: Between August 1993 and December 1998, 82 patients with pathologically confirmed GBM received external beam radiotherapy (EBRT) at the University of Maryland Medical Center. Of these 82 patients, 64 with a minimum follow-up duration of at least 1 month are the focus of this analysis. Of the 64 assessable patients, 33 patients were treated with EBRT alone (Group 1), and 31 patients received both EBRT plus a GK-SRS boost (Group 2). GK-SRS was administered to most patients within 6 weeks of the completion of EBRT. The median EBRT dose was 59.7 Gy (range, 28-70.2 Gy), and the median GK-SRS dose to the prescription volume was 17.1 Gy (range, 10-28 Gy). The median age of the study population was 50.4 years, and the median pretreatment Karnofsky performance status was 80. Patient-, tumor-, and treatment-related variables were analyzed by Cox regression analysis, and survival curves were generated by the Kaplan-Meier product limit. RESULTS: Median overall survival for the entire cohort was 16 months, and the actuarial survival rate at 1, 2, and 3 years were 67, 40, and 26%, respectively. When comparing age, Karnofsky performance status, extent of resection, and tumor volume, no statistical differences where discovered between Group 1 versus Group 2. When comparing the overall survival of Group 1 versus Group 2, the median survival was 13 months versus 25 months, respectively (P = 0.034). Age, Karnofsky performance status, and the addition of GK-SRS were all found to be significant predictors of overall survival via Cox regression analysis. No acute Grade 3 or Grade 4 toxicity was encountered. CONCLUSION: The addition of a GK-SRS boost in conjunction with surgery and EBRT significantly improved the overall survival time in this retrospective series of patients with GBM. A prospective, randomized validation of the benefit of SRS awaits the results of the recently completed Radiation Therapy Oncology Group's trial RTOG 93-05.

Original languageEnglish (US)
Pages (from-to)41-46
Number of pages6
JournalNeurosurgery
Volume50
Issue number1
DOIs
StatePublished - Jan 2002
Externally publishedYes

Fingerprint

Radiosurgery
Glioblastoma
Radiotherapy
Karnofsky Performance Status
Survival
Regression Analysis
Radiation Oncology
Therapeutics
Tumor Burden
Prescriptions
Survival Rate

Keywords

  • Gamma knife
  • Glioblastoma multiforme
  • Radiotherapy
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Nwokedi, E. C., DiBiase, S. J., Jabbour, S., Herman, J., Amin, P., & Chin, L. S. (2002). Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery, 50(1), 41-46. https://doi.org/10.1097/00006123-200201000-00009

Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. / Nwokedi, Emmanuel C.; DiBiase, Steven J.; Jabbour, Salma; Herman, Joseph; Amin, Pradip; Chin, Lawrence S.

In: Neurosurgery, Vol. 50, No. 1, 01.2002, p. 41-46.

Research output: Contribution to journalArticle

Nwokedi, EC, DiBiase, SJ, Jabbour, S, Herman, J, Amin, P & Chin, LS 2002, 'Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme', Neurosurgery, vol. 50, no. 1, pp. 41-46. https://doi.org/10.1097/00006123-200201000-00009
Nwokedi, Emmanuel C. ; DiBiase, Steven J. ; Jabbour, Salma ; Herman, Joseph ; Amin, Pradip ; Chin, Lawrence S. / Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. In: Neurosurgery. 2002 ; Vol. 50, No. 1. pp. 41-46.
@article{01608a804a0f4367a6677a4efde85ce9,
title = "Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme",
abstract = "OBJECTIVE: Stereotactic radiosurgery (SRS) has become an effective therapeutic modality for the treatment of patients with glioblastoma multiforme (GBM). This retrospective review evaluates the impact of SRS delivered on a gamma knife (GK) unit as an adjuvant therapy in the management of patients with GBM. METHODS: Between August 1993 and December 1998, 82 patients with pathologically confirmed GBM received external beam radiotherapy (EBRT) at the University of Maryland Medical Center. Of these 82 patients, 64 with a minimum follow-up duration of at least 1 month are the focus of this analysis. Of the 64 assessable patients, 33 patients were treated with EBRT alone (Group 1), and 31 patients received both EBRT plus a GK-SRS boost (Group 2). GK-SRS was administered to most patients within 6 weeks of the completion of EBRT. The median EBRT dose was 59.7 Gy (range, 28-70.2 Gy), and the median GK-SRS dose to the prescription volume was 17.1 Gy (range, 10-28 Gy). The median age of the study population was 50.4 years, and the median pretreatment Karnofsky performance status was 80. Patient-, tumor-, and treatment-related variables were analyzed by Cox regression analysis, and survival curves were generated by the Kaplan-Meier product limit. RESULTS: Median overall survival for the entire cohort was 16 months, and the actuarial survival rate at 1, 2, and 3 years were 67, 40, and 26{\%}, respectively. When comparing age, Karnofsky performance status, extent of resection, and tumor volume, no statistical differences where discovered between Group 1 versus Group 2. When comparing the overall survival of Group 1 versus Group 2, the median survival was 13 months versus 25 months, respectively (P = 0.034). Age, Karnofsky performance status, and the addition of GK-SRS were all found to be significant predictors of overall survival via Cox regression analysis. No acute Grade 3 or Grade 4 toxicity was encountered. CONCLUSION: The addition of a GK-SRS boost in conjunction with surgery and EBRT significantly improved the overall survival time in this retrospective series of patients with GBM. A prospective, randomized validation of the benefit of SRS awaits the results of the recently completed Radiation Therapy Oncology Group's trial RTOG 93-05.",
keywords = "Gamma knife, Glioblastoma multiforme, Radiotherapy, Stereotactic radiosurgery",
author = "Nwokedi, {Emmanuel C.} and DiBiase, {Steven J.} and Salma Jabbour and Joseph Herman and Pradip Amin and Chin, {Lawrence S.}",
year = "2002",
month = "1",
doi = "10.1097/00006123-200201000-00009",
language = "English (US)",
volume = "50",
pages = "41--46",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme

AU - Nwokedi, Emmanuel C.

AU - DiBiase, Steven J.

AU - Jabbour, Salma

AU - Herman, Joseph

AU - Amin, Pradip

AU - Chin, Lawrence S.

PY - 2002/1

Y1 - 2002/1

N2 - OBJECTIVE: Stereotactic radiosurgery (SRS) has become an effective therapeutic modality for the treatment of patients with glioblastoma multiforme (GBM). This retrospective review evaluates the impact of SRS delivered on a gamma knife (GK) unit as an adjuvant therapy in the management of patients with GBM. METHODS: Between August 1993 and December 1998, 82 patients with pathologically confirmed GBM received external beam radiotherapy (EBRT) at the University of Maryland Medical Center. Of these 82 patients, 64 with a minimum follow-up duration of at least 1 month are the focus of this analysis. Of the 64 assessable patients, 33 patients were treated with EBRT alone (Group 1), and 31 patients received both EBRT plus a GK-SRS boost (Group 2). GK-SRS was administered to most patients within 6 weeks of the completion of EBRT. The median EBRT dose was 59.7 Gy (range, 28-70.2 Gy), and the median GK-SRS dose to the prescription volume was 17.1 Gy (range, 10-28 Gy). The median age of the study population was 50.4 years, and the median pretreatment Karnofsky performance status was 80. Patient-, tumor-, and treatment-related variables were analyzed by Cox regression analysis, and survival curves were generated by the Kaplan-Meier product limit. RESULTS: Median overall survival for the entire cohort was 16 months, and the actuarial survival rate at 1, 2, and 3 years were 67, 40, and 26%, respectively. When comparing age, Karnofsky performance status, extent of resection, and tumor volume, no statistical differences where discovered between Group 1 versus Group 2. When comparing the overall survival of Group 1 versus Group 2, the median survival was 13 months versus 25 months, respectively (P = 0.034). Age, Karnofsky performance status, and the addition of GK-SRS were all found to be significant predictors of overall survival via Cox regression analysis. No acute Grade 3 or Grade 4 toxicity was encountered. CONCLUSION: The addition of a GK-SRS boost in conjunction with surgery and EBRT significantly improved the overall survival time in this retrospective series of patients with GBM. A prospective, randomized validation of the benefit of SRS awaits the results of the recently completed Radiation Therapy Oncology Group's trial RTOG 93-05.

AB - OBJECTIVE: Stereotactic radiosurgery (SRS) has become an effective therapeutic modality for the treatment of patients with glioblastoma multiforme (GBM). This retrospective review evaluates the impact of SRS delivered on a gamma knife (GK) unit as an adjuvant therapy in the management of patients with GBM. METHODS: Between August 1993 and December 1998, 82 patients with pathologically confirmed GBM received external beam radiotherapy (EBRT) at the University of Maryland Medical Center. Of these 82 patients, 64 with a minimum follow-up duration of at least 1 month are the focus of this analysis. Of the 64 assessable patients, 33 patients were treated with EBRT alone (Group 1), and 31 patients received both EBRT plus a GK-SRS boost (Group 2). GK-SRS was administered to most patients within 6 weeks of the completion of EBRT. The median EBRT dose was 59.7 Gy (range, 28-70.2 Gy), and the median GK-SRS dose to the prescription volume was 17.1 Gy (range, 10-28 Gy). The median age of the study population was 50.4 years, and the median pretreatment Karnofsky performance status was 80. Patient-, tumor-, and treatment-related variables were analyzed by Cox regression analysis, and survival curves were generated by the Kaplan-Meier product limit. RESULTS: Median overall survival for the entire cohort was 16 months, and the actuarial survival rate at 1, 2, and 3 years were 67, 40, and 26%, respectively. When comparing age, Karnofsky performance status, extent of resection, and tumor volume, no statistical differences where discovered between Group 1 versus Group 2. When comparing the overall survival of Group 1 versus Group 2, the median survival was 13 months versus 25 months, respectively (P = 0.034). Age, Karnofsky performance status, and the addition of GK-SRS were all found to be significant predictors of overall survival via Cox regression analysis. No acute Grade 3 or Grade 4 toxicity was encountered. CONCLUSION: The addition of a GK-SRS boost in conjunction with surgery and EBRT significantly improved the overall survival time in this retrospective series of patients with GBM. A prospective, randomized validation of the benefit of SRS awaits the results of the recently completed Radiation Therapy Oncology Group's trial RTOG 93-05.

KW - Gamma knife

KW - Glioblastoma multiforme

KW - Radiotherapy

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=0036365966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036365966&partnerID=8YFLogxK

U2 - 10.1097/00006123-200201000-00009

DO - 10.1097/00006123-200201000-00009

M3 - Article

VL - 50

SP - 41

EP - 46

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -